Bank of New York Mellon’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-645,973
| Closed | -$3.9M | – | 4247 |
|
|
2019
Q4 | $3.9M | Buy |
645,973
+7,398
| +1% | +$42.8K | ﹤0.01% | 2458 |
|
|
2019
Q3 | $2.3M | Sell |
638,575
-12,017
| -2% | -$46.3K | ﹤0.01% | 2677 |
|
|
2019
Q2 | $1.74M | Buy |
650,592
+14,757
| +2% | +$43.6K | ﹤0.01% | 2870 |
|
|
2019
Q1 | $1.88M | Buy |
635,835
+14,290
| +2% | +$35.1K | ﹤0.01% | 2802 |
|
|
2018
Q4 | $988K | Sell |
621,545
-9,316
| -1% | -$26.3K | ﹤0.01% | 3112 |
|
|
2018
Q3 | $2.32M | Buy |
630,861
+9,185
| +1% | +$27.4K | ﹤0.01% | 2767 |
|
|
2018
Q2 | $1.76M | Sell |
621,676
-4,993
| -0.8% | -$17K | ﹤0.01% | 2928 |
|
|
2018
Q1 | $2.33M | Buy |
626,669
+38,850
| +7% | +$127K | ﹤0.01% | 2724 |
|
|
2017
Q4 | $1.69M | Sell |
587,819
-17,474
| -3% | -$63.5K | ﹤0.01% | 2939 |
|
|
2017
Q3 | $2.72M | Sell |
605,293
-6,341
| -1% | -$28.2K | ﹤0.01% | 2654 |
|
|
2017
Q2 | $2.81M | Buy |
611,634
+62,515
| +11% | +$251K | ﹤0.01% | 2644 |
|
|
2017
Q1 | $2.31M | Buy |
549,119
+585
| +0.1% | +$2.43K | ﹤0.01% | 2767 |
|
|
2016
Q4 | $2.27M | Buy |
548,534
+35,943
| +7% | +$191K | ﹤0.01% | 2774 |
|
|
2016
Q3 | $4.15M | Sell |
512,591
-28,960
| -5% | -$246K | ﹤0.01% | 2334 |
|
|
2016
Q2 | $4.22M | Buy |
541,551
+259
| +0% | +$2.22K | ﹤0.01% | 2294 |
|
|
2016
Q1 | $4.18M | Sell |
541,292
-20,138
| -4% | -$147K | ﹤0.01% | 2270 |
|
|
2015
Q4 | $6.06M | Buy |
561,430
+16,393
| +3% | +$149K | ﹤0.01% | 2112 |
|
|
2015
Q3 | $3.77M | Sell |
545,037
-100,825
| -16% | -$821K | ﹤0.01% | 2400 |
|
|
2015
Q2 | $5.72M | Buy |
645,862
+20,926
| +3% | +$198K | ﹤0.01% | 2266 |
|
|
2015
Q1 | $6.16M | Sell |
624,936
-20,976
| -3% | -$262K | ﹤0.01% | 2202 |
|
|
2014
Q4 | $7.91M | Buy |
645,912
+8,589
| +1% | +$105K | ﹤0.01% | 2055 |
|
|
2014
Q3 | $6.36M | Buy |
637,323
+176,000
| +38% | +$1.63M | ﹤0.01% | 2162 |
|
|
2014
Q2 | $3.49M | Buy |
461,323
+2,437
| +0.5% | +$9.72K | ﹤0.01% | 2545 |
|
|
2014
Q1 | $1.51M | Sell |
458,886
-764
| -0.2% | -$2.67K | ﹤0.01% | 3064 |
|
|
2013
Q4 | $1.53M | Sell |
459,650
-13,475
| -3% | -$39.1K | ﹤0.01% | 3053 |
|
|
2013
Q3 | $1.43M | Buy |
473,125
+44,797
| +10% | +$307K | ﹤0.01% | 3049 |
|
|
2013
Q2 | $3.5M | Buy |
+428,328
| New | +$3.27M | ﹤0.01% | 2405 |
|
Bank of New York Mellon's ACHN Position: Q1 2020 in Review
Bank of New York Mellon sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 645,973 shares — an estimated $3.9M sold.
Bank of New York Mellon first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $7.91M in Q4 2014. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Bank of New York Mellon reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Bank of New York Mellon sold 645,973 Achillion Pharmaceuticals shares in Q1 2020, an estimated $3.9M.
- Bank of New York Mellon first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Bank of New York Mellon's Achillion Pharmaceuticals position peaked at $7.91M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Bank of New York Mellon's 13F filing for Q1 2020, filed 6 May 2020.